Aura Biosciences, Inc. (AURA)
- Previous Close
4.90 - Open
4.53 - Bid 3.84 x 200
- Ask 5.68 x 200
- Day's Range
4.34 - 5.38 - 52 Week Range
4.34 - 12.38 - Volume
266,682 - Avg. Volume
274,581 - Market Cap (intraday)
263.911M - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
-- - EPS (TTM)
-1.75 - Earnings Date May 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.00
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is based in Boston, Massachusetts.
www.aurabiosciences.comRecent News: AURA
View More
Performance Overview: AURA
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AURA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AURA
View MoreValuation Measures
Market Cap
246.32M
Enterprise Value
113.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.62
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.46%
Return on Equity (ttm)
-46.01%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-86.92M
Diluted EPS (ttm)
-1.75
Balance Sheet and Cash Flow
Total Cash (mrq)
151.09M
Total Debt/Equity (mrq)
12.35%
Levered Free Cash Flow (ttm)
-50.17M
Research Analysis: AURA
View MoreResearch Reports: AURA
View MoreDaily – Vickers Top Buyers & Sellers for 11/13/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/10/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/06/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.